"33" . "BDNF protein levels are decreased in transformed lymphoblasts from lithium-responsive patients with bipolar disorder"@en . "000259500500008" . . . "Brain-derived neurotrophic factor (BDNF) is a key factor in neuroplasticity and has been implicated in the affective disorders; studies have demonstrated elevated BDNF in patients taking lithium and other mood stabilizers. The objective of our study was to analyze BDNF in lithium-responsive patients with bipolar disorder (BD) to further understand the role of BDNF in the pathophysiology of BD. Methods: Using enzyme-linked immunosorbent assay, we measured transformed B lymphocytes for BDNF protein. Results: BDNF levels were 36% lower in lymphoblasts from patients with BD (n = 12), compared with matched control participants (n = 13), and 55% lower when compared with their unaffected relatives (n = 14). Lithium significantly decreased BDNF levels in patients with BD and healthy control participants, although BDNF levels remained lower (33%) in the BID group posttreatment. Conclusion: Decreased BDNF may constitute part of the pathophysiologic process of BID in a lithium-responsive subgroup of individuals with this disease. A compensatory mechanism protecting the genetically predisposed unaffected relatives from phenotypic expression of BID is suggested."@en . "N" . . . "1"^^ . . "Brain-derived neurotrophic factor (BDNF) is a key factor in neuroplasticity and has been implicated in the affective disorders; studies have demonstrated elevated BDNF in patients taking lithium and other mood stabilizers. The objective of our study was to analyze BDNF in lithium-responsive patients with bipolar disorder (BD) to further understand the role of BDNF in the pathophysiology of BD. Methods: Using enzyme-linked immunosorbent assay, we measured transformed B lymphocytes for BDNF protein. Results: BDNF levels were 36% lower in lymphoblasts from patients with BD (n = 12), compared with matched control participants (n = 13), and 55% lower when compared with their unaffected relatives (n = 14). Lithium significantly decreased BDNF levels in patients with BD and healthy control participants, although BDNF levels remained lower (33%) in the BID group posttreatment. Conclusion: Decreased BDNF may constitute part of the pathophysiologic process of BID in a lithium-responsive subgroup of individuals with this disease. A compensatory mechanism protecting the genetically predisposed unaffected relatives from phenotypic expression of BID is suggested." . . "BDNF protein levels are decreased in transformed lymphoblasts from lithium-responsive patients with bipolar disorder"@en . "Journal of Psychiatry & Neuroscience" . . "BDNF protein levels are decreased in transformed lymphoblasts from lithium-responsive patients with bipolar disorder" . . . . "BDNF protein levels are decreased in transformed lymphoblasts from lithium-responsive patients with bipolar disorder" . "RIV/00216208:11120/08:43906867" . "RIV/00216208:11120/08:43906867!RIV13-MSM-11120___" . "5" . . . "357707" . "Alda, Martin" . "[7A782E09C35E]" . "CA - Kanada" . "11120" . "5"^^ . . . . "9"^^ . "lithium; enzyme-linked immunosorbent assay; brain-derived neurotrophic factor; bipolar disorder"@en . "1180-4882" .